Neurocrine biosciences publishes analysis showing long-term efficacy and a consistent safety profile of ingrezza® (valbenazine) capsules in older adults with tardive dyskinesia in the journal of clinical psychiatry

Post-hoc analysis of higher risk older adults showed substantial and sustained improvements in tardive dyskinesia symptoms with no new treatment-emergent adverse events of clinical concern san diego , april 24, 2025 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced publication of a post-hoc analysis from two 48-week studies, the kinect® 3 extension and kinect® 4, demonstrating the long-term safety profile and robust efficacy of ingrezza® (valbenazine) capsules in adults aged 65 years and older with tardive dyskinesia (td) in the journal of clinical psychiatry. this represents the first and only published peer-reviewed analysis of a vesicular monoamine transporter 2 inhibitor for the treatment of td in older adults (≥65 years), a group at higher risk for td and associated consequences.
NBIX Ratings Summary
NBIX Quant Ranking